Sorrento Therapeutics Stock News

Healthcare > Biotechnology

Buy SRNEQ

*Your capital is at risk

$0.351

+0 (+0%)

At Close: Jul 18, 2023

Reviewing SQZ Biotechnologies (NYSE:SQZ) and Sorrento Therapeutics (OTCMKTS:SRNEQ)

01:50am, Monday, 12'th Jan 2026

Institutional and Insider Ownership 0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are owned by institutional investors.

Sorrento Therapeutics (OTCMKTS:SRNEQ) versus LadRx (OTCMKTS:CYTR) Financial Contrast

01:26am, Wednesday, 31'st Dec 2025

Profitability This table compares LadRx and Sorrento Therapeutics' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets LadRx N/A -67.61% -45.39% Sorrento

Contrasting Sorrento Therapeutics (OTCMKTS:SRNEQ) and LadRx (OTCMKTS:CYTR)

01:17am, Saturday, 13'th Dec 2025

Institutional and Insider Ownership 0.1% of LadRx shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 12.8% of LadRx sh

Sorrento Therapeutics (OTCMKTS:SRNEQ) and bluebird bio (NASDAQ:BLUE) Financial Comparison

01:18am, Monday, 20'th May 2024

Sorrento Therapeutics (OTCMKTS:SRNEQ – Get Free Report) and bluebird bio (NASDAQ:BLUE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compar

Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company

11:38am, Friday, 22'nd Sep 2023

SAN DIEGO, Sept. 22, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "Company"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to tre

Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19

09:00am, Tuesday, 12'th Sep 2023

SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) announced today positive topline results of a pivotal Phase 3 study of Sorrento's oral Mpro inh

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients

09:00am, Thursday, 07'th Sep 2023

SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") announced today positive Phase 2a top-line clinical trial results for the RTX program.

Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders

09:00am, Thursday, 27'th Jul 2023

SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer,

3 Penny Stocks to Make You the Millionaire Next Door

06:07am, Thursday, 25'th May 2023

When it comes to investing, penny stocks often evoke a sense of intrigue and opportunity. These low-priced securities, typically traded under $5 per share, can potentially deliver substantial gains qu

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by